Evidence review · from the 250-topic plan
The interactions file: what actually conflicts with GLP-1s — and the absorption story under all of it
The classic drug-interaction list for tirzepatide and semaglutide is refreshingly short — no cytochrome drama, no grapefruit folklore — because these are peptides cleared like proteins, not pills fighting over liver enzymes. The real story is mechanical: delayed gastric emptying can change when and how completely other oral medications absorb, which matters most for narrow-window drugs (levothyroxine and warfarin earn monitoring conversations, not fear), for oral contraceptives on tirzepatide specifically (a genuine label caveat with its own article), and for diabetes medications — insulin and sulfonylureas — where the interaction is pharmacological teamwork gone too well: hypoglycemia, managed by prescriber-side dose adjustments. Add the two absolutes (never two GLP-1 products concurrently; tell your anesthesia team before sedation) and you have the whole file — plus the discipline that makes it work: a complete med-and-supplement list in your prescriber's hands.
Why the list is short
Small-molecule drugs collide in the liver's enzyme systems; peptides mostly don't play there — semaglutide and tirzepatide are broken down like proteins, which deletes whole categories of classic interaction. The label-level result: few named conflicts, and the ones that exist route through two doors — the stomach's new pace, and additive effects with other glucose-lowering drugs. Understand those two doors and you understand the file.
The oral-absorption story
Slower emptying means oral drugs can reach the intestine — where most absorption happens — later, and occasionally less completely, with the effect largest during initiation and escalation when the emptying delay peaks. Practical translations: levothyroxine (a famously finicky absorber) merits a TSH check a couple of months into therapy and after big dose steps rather than assumptions; warfarin users should keep their INR schedule honest through the start-up months; time-critical drugs (some seizure meds, transplant meds) belong in an explicit prescriber conversation before day one. What this story is not: a reason to fear ordinary medications — for most drugs the timing shift is clinically invisible. It's a monitoring story, and monitoring is cheap.
The diabetes-med teamwork problem
Combine a GLP-1 with insulin or a sulfonylurea and both are pushing glucose the same direction — the “interaction” is success overshooting into hypoglycemia. This is standard, well-managed territory: prescribers routinely reduce insulin or sulfonylurea doses when starting the class, then re-titrate as weight and glucose fall. The patient-side jobs: know your low-sugar symptoms (shakiness, sweating, confusion, racing heart), keep fast carbs reachable early on, and report lows promptly — they're dose-adjustment data, not failures. Metformin, for the record, pairs without drama.
The two absolutes
One GLP-1 at a time: no stacking semaglutide with tirzepatide, no “bridging” overlap regimens — switching is a clean handoff at the next scheduled dose, never a duet. Sedation disclosure: any procedure involving anesthesia or deep sedation needs your GLP-1 on the intake list — the emptying delay is exactly what anesthesia teams plan around, and the perioperative file covers the evolving protocols. Neither absolute is exotic; both are one honest sentence at the right moment.
Supplements — and the “natural booster” aisle
No supplement carries an established dangerous interaction with the class — the practical guidance is disclosure (especially anything with blood-sugar or blood-thinning claims) and timing common sense for the finicky absorbers above. The consumer-protection note this site owes you: the “natural GLP-1 booster” supplement genre — berberine-as-“nature's-Ozempic,” assorted “GLP-1 activators” — is marketing arbitrage on this class's fame, not an interaction risk so much as a wallet interaction: modest-at-best evidence sold at pharmaceutical adjacency. Your prescriber's med list is still the place they belong, if only for honesty's sake. And the meta-lesson of this whole file: a program with real clinicians is one where “does my medication list matter?” gets answered before the first vial ships — flag-2 material when the quiz never asked. Intake that actually asks ↗
FAQ
What drugs interact with semaglutide or tirzepatide?
The short list: insulin and sulfonylureas (hypoglycemia teamwork — prescriber adjusts doses), oral contraceptives on tirzepatide (four-week backup windows per label), and narrow-window orals like levothyroxine and warfarin (monitoring conversations). Never combine two GLP-1 products.
Does GLP-1 therapy affect my other pills?
Delayed stomach emptying can shift when oral drugs absorb — clinically invisible for most medications, monitoring-worthy for finicky ones, largest during initiation and dose escalations.
Can I take metformin with a GLP-1?
Yes — a routine, low-drama pairing in diabetes care; hypoglycemia risk concentrates with insulin and sulfonylureas instead.
Do supplements interact with GLP-1s?
No established dangerous interactions — disclose everything anyway, and treat “natural GLP-1 booster” products as marketing adjacency rather than medicine.
Sources
- Zepbound/Mounjaro and Wegovy/Ozempic prescribing information — interaction and oral-absorption language.
- Hypoglycemia combination guidance with insulin/sulfonylureas.
- Levothyroxine and warfarin monitoring practice references.